1
|
Švecová P, Baron D, Schug KA, Pluháček T, Petr J. Ultra-trace determination of oxaliplatin impurities by sweeping-MEKC-ICP-MS. Microchem J 2022. [DOI: 10.1016/j.microc.2021.106967] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
2
|
Godzieba M, Ciesielski S. Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases. Curr Cancer Drug Targets 2021; 20:19-32. [PMID: 31589125 DOI: 10.2174/1568009619666191007112516] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Revised: 06/11/2019] [Accepted: 06/24/2019] [Indexed: 02/08/2023]
Abstract
Cancer and infectious diseases are one of the greatest challenges of modern medicine. An unhealthy lifestyle, the improper use of drugs, or their abuse are conducive to the increase of morbidity and mortality caused by these diseases. The imperfections of drugs currently used in therapy for these diseases and the increasing problem of drug resistance have forced a search for new substances with therapeutic potential. Throughout history, plants, animals, fungi and microorganisms have been rich sources of biologically active compounds. Even today, despite the development of chemistry and the introduction of many synthetic chemotherapeutics, a substantial part of the new compounds being tested for treatment are still of natural origin. Natural compounds exhibit a great diversity of chemical structures, and thus possess diverse mechanisms of action and molecular targets. Nucleic acids seem to be a good molecular target for substances with anticancer potential in particular, but they may also be a target for antimicrobial compounds. There are many types of interactions of small-molecule ligands with DNA. This publication focuses on the intercalation process. Intercalators are compounds that usually have planar aromatic moieties and can insert themselves between adjacent base pairs in the DNA helix. These types of interactions change the structure of DNA, leading to various types of disorders in the functioning of cells and the cell cycle. This article presents the most promising intercalators of natural origin, which have aroused interest in recent years due to their therapeutic potential.
Collapse
Affiliation(s)
- Martyna Godzieba
- Department of Environmental Biotechnology, Faculty of Environmental Sciences, University of Warmia and Mazury in Olsztyn, ul. Sloneczna 45 G, 10-917 Olsztyn, Poland
| | - Slawomir Ciesielski
- Department of Environmental Biotechnology, Faculty of Environmental Sciences, University of Warmia and Mazury in Olsztyn, ul. Sloneczna 45 G, 10-917 Olsztyn, Poland
| |
Collapse
|
3
|
Deng J, Ding HH, Long JL, Lin SY, Liu M, Zhang XQ, Xin WJ, Ruan X. Oxaliplatin-induced neuropathic pain involves HOXA6 via a TET1-dependent demethylation of the SOX10 promoter. Int J Cancer 2020; 147:2503-2514. [PMID: 32428246 DOI: 10.1002/ijc.33106] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 03/25/2020] [Accepted: 05/05/2020] [Indexed: 12/21/2022]
Abstract
Chemotherapy-induced neuropathic pain is a common dose-limiting side effect of cancer treatment but the underlying mechanisms are largely unknown. Here, we used a whole-genome expression microarray and gene ontology analysis to identify the upregulation of a sequence-specific DNA-binding protein, HOXA6, in the spinal dorsal horn on Day 10 after injection of rats with oxaliplatin. Genetic disruption of HOXA6 with siRNAs alleviated mechanical allodynia after oxaliplatin administration. Reduced representation bisulfite sequencing assays indicated that oxaliplatin decreased the methylation levels of the SOX10 promoter but not of HOXA6. TET1 was also upregulated by oxaliplatin. Genetic disruption of TET1 with siRNA blocked the promoter demethylation of SOX10 and the upregulation of HOXA6 and SOX10. Importantly, inhibition of SOX10 by intrathecal application of SOX10 siRNA ameliorated the mechanical allodynia induced by oxaliplatin and downregulated the expression of HOXA6. Consistently, overexpression of SOX10 through intraspinal injection of AAV-SOX10-EGFP produced mechanical allodynia and upregulated the expression of spinal dorsal horn HOXA6. Moreover, chromatin immunoprecipitation assays demonstrated that oxaliplatin increased the binding of SOX10 to the promoter region of HOXA6. Taken together, our data suggest that HOXA6 upregulation through the TET1-mediated promoter demethylation of SOX10 may contribute to oxaliplatin-induced neuropathic pain.
Collapse
Affiliation(s)
- Jie Deng
- Department of Anesthesia and Pain Medicine, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Huan-Huan Ding
- Guangdong Province Key Laboratory of Brain Function and Disease, Department of physiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China
| | - Jia-Li Long
- Department of Pathology, the Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China
| | - Su-Yan Lin
- Guangdong Province Key Laboratory of Brain Function and Disease, Department of physiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China
| | - Meng Liu
- Guangdong Province Key Laboratory of Brain Function and Disease, Department of physiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China
| | - Xue-Qin Zhang
- The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
| | - Wen-Jun Xin
- Guangdong Province Key Laboratory of Brain Function and Disease, Department of physiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China
| | - Xiangcai Ruan
- Department of Anesthesia and Pain Medicine, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China.,Department of Anesthesia and Pain Medicine, Second Affiliated Hospital of South China University of Technology, Guangzhou, China
| |
Collapse
|